Capricor's DMD Cell Therapy Has HOPE, But Market Is Unsure

 
• By Lucie Ellis-Taitt

Capricor will start a Phase II trial in the first quarter of 2018 for its regenerative cell therapy CAP-1002 in Duchenne muscular dystrophy following positive results in an early-stage trial – the stem cell product was dropped by Capricor's big pharma partner Johnson & Johnson earlier this year.

MUSCULAR DYSTROPHY words written on label tag with medicine,syringe,keyboard and stethoscope
Carpricor pursues stem cell approach for cardiomyopathy in muscular dystrophy

More from Clinical Trials

More from R&D